RCT in 108 adults with Crohn's disease and secondary loss of response to ustekinumab: after IV reinduction, dosing every 4 vs every 8 weeks gave no significant difference in week-48 steroid-free clinical remission (15% vs 19%; P=0.5).
RCTn = 108
Bossuyt et al. The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn's Disease: Results of the REScUE Study